RxDoctor Payments Data

Joseph Zitarelli, MD

Surgery · Frederick, MDNPI 1720012966

Payments from drug & device makers

$1,740in general payments, 2019–2025

Across 75 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$581
  • Organogenesis Inc.$397
  • Integra Lifesciences Corporation$158
  • Reapplix Inc.$154
  • Kerecis Limited$114
  • Urgo Medical North America, LLC$52
  • plus $285 from 11 others

What the payments were for

  • Travel & lodging$1468%
  • Food & beverage$1,59492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew39$581
Organogenesis Inc.6$397
Integra Lifesciences Corporation10$158
Reapplix Inc.3$154
Kerecis Limited1$114
Urgo Medical North America, LLC3$52
Solventum Corporation2$43
Bioventus LLC2$34
Progenacare Global, LLC1$33
Misonix Inc1$28
Medline Industries LP1$26
Hydrofera LLC1$26
La Jolla Pharmaceutical Company1$22
Hartmann USA, Inc.1$20
Mimedx Group, Inc.1$19
Cashflow Solutions, LLC1$19
OVIK Health, LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,740 in reported general payments places this provider in the 55th percentile of 493 surgery providers in Maryland.

See all surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$188,684
Medicare patients
217
Services billed
3,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.53$73,314
Gentamicin Sulfate28$1,024
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$354
Pentoxifylline13$304
Nystatin13$150
Doxycycline Hyclate17$132
Cephalexin13$98
Ciprofloxacin Hcl12$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$581$73,31453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 493 surgery providers in Maryland.

Other surgery in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →